Denali Therapeutics Inc (DNLI) — Cash Flow Reinvestment Rate
Denali Therapeutics Inc (DNLI) has a Cash Flow Reinvestment Rate of 0.71x as of December 2020, reinvesting $367.34 Million (capex $1.19 Million plus investments $-366.14 Million) from operating cash flow of $513.91 Million. Check how high is Denali Therapeutics Inc's earnings quality to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Denali Therapeutics Inc Cash Flow Reinvestment Rate (2018–2020)
Historical reinvestment intensity for Denali Therapeutics Inc across 2 annual periods. Explore DNLI long-term investment intensity to see how much of total assets are deployed in long-term investments.
Annual Cash Flow Reinvestment Rate for Denali Therapeutics Inc (2018–2020)
Year-by-year capital reinvestment analysis for Denali Therapeutics Inc. For live market cap and broader valuation context, see market cap of Denali Therapeutics Inc.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2020 | 1.50x | $623.21 Million | $416.15 Million | $3.10 Million | ▼ -73.9% |
| 2018 | 5.74x | $287.42 Million | $50.12 Million | $3.39 Million | — |